Kodiak Sciences reported that two vision-focused candidates matched aflibercept in a Phase 3 clinical trial, positioning the company to pursue FDA approval of one eye disease asset during the year. The company’s results aim to demonstrate therapeutic performance against a standard-of-care anti-VEGF comparator. If regulatory submission proceeds as planned, the near-term spotlight will shift to final labeling strategy, manufacturing scale-up, and differentiation—especially as ophthalmology remains a crowded arena for next-generation VEGF targeting and durable dosing concepts.